CMAX, IDT OPENS A NEW FACILITY IN ADELAIDE
Established in 1993, CMAX is one of Australia’s largest, longest running and most experienced, dedicated clinical trials unit.
Our team specialises in a range of early-phase clinical trials, including first-time in human-studies – of which we’ve conducted more than 100 to date.
With an impressive global regulatory history and a database of more than 13,000 active volunteers, our brand new 50-bed Phase I (through to Phase II-IV) unit includes a 24-bed ambulatory cardiac telemetry monitoring system and is centrally located to Adelaide’s Biomed City.
LOCAL & GLOBAL PARTNERSHIPS
“Our specialist teams strive to ensure the very best outcomes for patients and clients whilst conducting leading research with agile startups as well as the world’s top pharmaceutical companies. We hold ourselves to the highest standards, working with our government and industry partners to benefit the health outcomes of communities world-wide.”
Mr Graeme Kaufman, Chairman, IDT Australia.
ASSISTED STUDY APPROVALS
By using the CTN scheme we can assist you fast-track your clinical trial, eliminating the time and cost associated with filing an Investigational New Drug (IND) application.
Studies are initiated on approval by a local human research ethics committee (HREC), typically within six weeks of submission. The Therapeutic Goods Administration (TGA), Australia’s regulatory body, is notified of the impending study by way of the Australian Clinical Trial Notification (CTN), but it does not need to give approval before commencement.
AUSTRALIAN R&D TAX INCENTIVES
All of our studies are fully ICH GCP compliant and comply with the registration requirements of the US FDA, EMEA, Japanese MHW and Canadian HPB; we have been US FDA-audited.
We can assist our overseas clients register for the Australian R&D Tax Incentive scheme. This allows eligible companies to claim up to a 45% rebate on qualifying R&D spend – for more information contact our experienced team today.
InCarda Therapeutics, Inc. is a biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions and diseases.
In this video Narsi Rangachari, M.Pharm, Chief Operating Officer and Co-Founder discusses why InCarda entrusted CMAX with his business’s clinic trials.
On Friday 29 April IDT Australia Chairman Mr Graeme Kaufman, together with The Hon. Katrine Hildyard MP Assistant Minister to the Premier, Member for Reynell representing the Hon. Jack Snelling MP Minister for Health Industries, launched a new purpose built clinical trials facility in central Adelaide.
We have run a large number of trials in a wide range of therapeutic areas:
|Pain / Anaesthesia (inc. S8)|
|Metabolism / Endocrinology|
|Allergy / Respiratory|